Stock Analysis

MicroTech Medical (Hangzhou) First Half 2024 Earnings: Misses Expectations

Published
SEHK:2235

MicroTech Medical (Hangzhou) (HKG:2235) First Half 2024 Results

Key Financial Results

  • Revenue: CN¥150.8m (up 36% from 1H 2023).
  • Net loss: CN¥37.7m (loss widened by 102% from 1H 2023).
  • CN¥0.09 loss per share (further deteriorated from CN¥0.04 loss in 1H 2023).
SEHK:2235 Earnings and Revenue Growth September 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

MicroTech Medical (Hangzhou) Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 80%.

Looking ahead, revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are up 12% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of MicroTech Medical (Hangzhou)'s balance sheet and an in-depth analysis of the company's financial position.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.